QS11 (QS-11) is a novel and potent inhibitor of GTPase activating protein of ADP-ribosylation factor 1 (ARF-GAP1) [EC50 of 1.5 µM] with anticancer activity.
Physicochemical Properties
| Molecular Formula | C36H33N5O2 |
| Molecular Weight | 567.69 |
| Exact Mass | 567.263 |
| CAS # | 944328-88-5 |
| Related CAS # | 944328-88-5; |
| PubChem CID | 42623900 |
| Appearance | White to off-white solid powder |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 852.2±75.0 °C at 760 mmHg |
| Flash Point | 469.2±37.1 °C |
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
| Index of Refraction | 1.685 |
| LogP | 6.67 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 10 |
| Heavy Atom Count | 43 |
| Complexity | 842 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | C(C1C=CC(C2C=CC=CC=2)=CC=1)N1C=NC2C(=NC(=NC1=2)OC1C=CC2CCCC=2C=1)N[C@H](CO)CC1C=CC=CC=1 |
| InChi Key | DOKZLKDGUQWMSX-HKBQPEDESA-N |
| InChi Code | InChI=1S/C36H33N5O2/c42-23-31(20-25-8-3-1-4-9-25)38-34-33-35(40-36(39-34)43-32-19-18-28-12-7-13-30(28)21-32)41(24-37-33)22-26-14-16-29(17-15-26)27-10-5-2-6-11-27/h1-6,8-11,14-19,21,24,31,42H,7,12-13,20,22-23H2,(H,38,39,40)/t31-/m0/s1 |
| Chemical Name | (2S)-2-[[2-(2,3-Dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]purin-6-yl]amino]-3-phenylpropan-1-ol |
| Synonyms | QS-11 QS11 QS 11 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | It is possible that QS11 controls Wnt/β-catenin signaling via influencing protein trafficking because it binds to and inhibits the GTPase-activating protein ARFGAP1 [1]. In the presence of Wnt-3a conditioned media, QS11 (2.5 μM) can activate the Super(8X)TOPFlash reporter gene 200-fold, whereas Wnt-3a treatment alone can boost reporter gene activity by 40-fold [2]. QS11 has strong anti-HEK293 and human primary fibroblast activity (EC50=0.5 μM) and minimal cytotoxicity [2]. In vitro, QS11 efficiently inhibits the migration of human breast cancer cells that have spread [2]. |
| References |
[1]. Structure-activity Relationship Studies of QS11, a Small Molecule Wnt Synergistic Agonist. Bioorg Med Chem Lett. 2015 Nov 1; 25(21): 4838–4842. [2]. Small-molecule synergist of the Wnt/beta-catenin signaling pathway. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7444-8. |
| Additional Infomation | (2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol is a member of biphenyls. |
Solubility Data
| Solubility (In Vitro) | DMSO : ≥ 100 mg/mL (~176.16 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7615 mL | 8.8076 mL | 17.6152 mL | |
| 5 mM | 0.3523 mL | 1.7615 mL | 3.5230 mL | |
| 10 mM | 0.1762 mL | 0.8808 mL | 1.7615 mL |